Concordia Healthcare Corp. T.CXR.R

RBC Valuation for CXRX (USD$)

[TechTarget]

"We value Concordia shares by averaging the results of our P/E valuation and DCF analysis.

Applying a 10x multiple to our 2017 earnings forecast of $7.48 generates a value of $74.84. The

10x multiple represents a ~10% discount to the group average of ~11x. We believe a discount

relative to the group is appropriate, as the majority of the assets have lost or are nearing the

end of patent protection. Combined with a modest R&D pipeline, organic growth is challenged.

Our DCF value (9.5% WACC and a 0.5% terminal growth rate) equates to $79.65. The average of

our P/E and DCF values is $77.24, hence our $77 price target. There are no further acquisitions

included in our base case. We assume that Photofrin is approved for bile duct cancer in 2018."

[sanspeine]

This post has been removed in accordance with Community Policy

[Joseph_K]

I think RBC's applying a 10% discount to the group average multiple of 11x is fair.  Sure call it 10x earnings if you want.   It is still way below the 22x or so it reached 2 months ago. As they are estimating about $10/sh Canadian earnings for 2017, that has us trading at a 4x 2017 forward earnings multiple.   Where else can you find such a cheap stock? We are also roughly at

[TechTarget]

This is a revised target AS OF YESTERDAY!  $77 USD = over $100 CDN My stock analysis software has CXR as $143. Bashers of these targets are PAID BLOGGERS but the hedge fund scammers!  Or just dumb shorters who have no idea when the big boys will stop the games!   What I know is games do end...

[adamchess]

If only we could take your targets to the bank. This game is going on way too long. First PHM, then NHC, now CXR. what inning are we in - seems like the 20th?